Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) EBT (2019 - 2025)

Eton Pharmaceuticals' EBT history spans 7 years, with the latest figure at -$2.0 million for Q3 2025.

  • For Q3 2025, EBT fell 490.22% year-over-year to -$2.0 million; the TTM value through Sep 2025 reached -$6.5 million, down 22.18%, while the annual FY2024 figure was -$3.8 million, 452.69% down from the prior year.
  • EBT for Q3 2025 was -$2.0 million at Eton Pharmaceuticals, up from -$2.5 million in the prior quarter.
  • Across five years, EBT topped out at $5.1 million in Q1 2021 and bottomed at -$6.1 million in Q3 2021.
  • The 5-year median for EBT is -$1.6 million (2022), against an average of -$1.1 million.
  • The largest annual shift saw EBT surged 392.62% in 2023 before it tumbled 490.22% in 2025.
  • A 5-year view of EBT shows it stood at $1.0 million in 2021, then fell by 12.22% to $912000.0 in 2022, then plummeted by 320.29% to -$2.0 million in 2023, then surged by 74.56% to -$511000.0 in 2024, then tumbled by 282.58% to -$2.0 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's EBT are -$2.0 million (Q3 2025), -$2.5 million (Q2 2025), and -$1.5 million (Q1 2025).